OTCMKTS:HKMPF

Hikma Pharmaceuticals Competitors

$33.00
0.00 (0.00 %)
(As of 04/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$33.00
Now: $33.00
$33.00
50-Day Range
$30.15
MA: $31.76
$37.00
52-Week Range
$26.20
Now: $33.00
$42.00
Volume100 shs
Average Volume749 shs
Market Capitalization$8.00 billion
P/E Ratio22.00
Dividend Yield0.48%
Beta0.41

Competitors

Hikma Pharmaceuticals (OTCMKTS:HKMPF) Vs. ASAZY, AMADY, CKHUY, SWRAY, FJTSY, and ASHTY

Should you be buying HKMPF stock or one of its competitors? Companies in the industry of "private households" are considered alternatives and competitors to Hikma Pharmaceuticals, including ASSA ABLOY AB (publ) (ASAZY), Amadeus IT Group (AMADY), CK Hutchison (CKHUY), Swire Pacific (SWRAY), Fujitsu (FJTSY), and Ashtead Group (ASHTY).

Hikma Pharmaceuticals (OTCMKTS:HKMPF) and ASSA ABLOY AB (publ) (OTCMKTS:ASAZY) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Institutional & Insider Ownership

0.3% of ASSA ABLOY AB (publ) shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Dividends

Hikma Pharmaceuticals pays an annual dividend of $0.16 per share and has a dividend yield of 0.5%. ASSA ABLOY AB (publ) pays an annual dividend of $0.14 per share and has a dividend yield of 0.9%. Hikma Pharmaceuticals pays out 10.7% of its earnings in the form of a dividend. ASSA ABLOY AB (publ) pays out 29.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Profitability

This table compares Hikma Pharmaceuticals and ASSA ABLOY AB (publ)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hikma PharmaceuticalsN/AN/AN/A
ASSA ABLOY AB (publ)9.35%13.66%6.71%

Earnings and Valuation

This table compares Hikma Pharmaceuticals and ASSA ABLOY AB (publ)'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hikma Pharmaceuticals$2.21 billion3.62$486 million$1.5022.00
ASSA ABLOY AB (publ)$9.95 billion3.18$1.06 billion$0.4831.27

ASSA ABLOY AB (publ) has higher revenue and earnings than Hikma Pharmaceuticals. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than ASSA ABLOY AB (publ), indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Hikma Pharmaceuticals has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, ASSA ABLOY AB (publ) has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Hikma Pharmaceuticals and ASSA ABLOY AB (publ), as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hikma Pharmaceuticals01502.83
ASSA ABLOY AB (publ)241102.53

Summary

ASSA ABLOY AB (publ) beats Hikma Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Amadeus IT Group (OTCMKTS:AMADY) and Hikma Pharmaceuticals (OTCMKTS:HKMPF) are both business services companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Valuation and Earnings

This table compares Amadeus IT Group and Hikma Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amadeus IT Group$6.25 billion5.01$1.25 billion$3.3021.04
Hikma Pharmaceuticals$2.21 billion3.62$486 million$1.5022.00

Amadeus IT Group has higher revenue and earnings than Hikma Pharmaceuticals. Amadeus IT Group is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Amadeus IT Group and Hikma Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amadeus IT Group-4.16%1.50%0.55%
Hikma PharmaceuticalsN/AN/AN/A

Insider & Institutional Ownership

0.2% of Amadeus IT Group shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Amadeus IT Group and Hikma Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amadeus IT Group34302.00
Hikma Pharmaceuticals01502.83

Volatility and Risk

Amadeus IT Group has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, Hikma Pharmaceuticals has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500.

Summary

Amadeus IT Group beats Hikma Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

Hikma Pharmaceuticals (OTCMKTS:HKMPF) and CK Hutchison (OTCMKTS:CKHUY) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations.

Dividends

Hikma Pharmaceuticals pays an annual dividend of $0.16 per share and has a dividend yield of 0.5%. CK Hutchison pays an annual dividend of $0.13 per share and has a dividend yield of 1.6%. Hikma Pharmaceuticals pays out 10.7% of its earnings in the form of a dividend.

Analyst Recommendations

This is a summary of current ratings and target prices for Hikma Pharmaceuticals and CK Hutchison, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hikma Pharmaceuticals01502.83
CK Hutchison0000N/A

Insider & Institutional Ownership

0.0% of CK Hutchison shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Hikma Pharmaceuticals and CK Hutchison's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hikma Pharmaceuticals$2.21 billion3.62$486 million$1.5022.00
CK Hutchison$38.34 billion0.81$5.11 billionN/AN/A

CK Hutchison has higher revenue and earnings than Hikma Pharmaceuticals.

Volatility and Risk

Hikma Pharmaceuticals has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, CK Hutchison has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500.

Profitability

This table compares Hikma Pharmaceuticals and CK Hutchison's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hikma PharmaceuticalsN/AN/AN/A
CK HutchisonN/AN/AN/A

Summary

CK Hutchison beats Hikma Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

Swire Pacific (OTCMKTS:SWRAY) and Hikma Pharmaceuticals (OTCMKTS:HKMPF) are both transportation companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.

Institutional & Insider Ownership

0.1% of Swire Pacific shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Swire Pacific has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, Hikma Pharmaceuticals has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500.

Earnings and Valuation

This table compares Swire Pacific and Hikma Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Swire Pacific$10.93 billion2.81$1.15 billion$2.513.15
Hikma Pharmaceuticals$2.21 billion3.62$486 million$1.5022.00

Swire Pacific has higher revenue and earnings than Hikma Pharmaceuticals. Swire Pacific is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Dividends

Swire Pacific pays an annual dividend of $0.23 per share and has a dividend yield of 2.9%. Hikma Pharmaceuticals pays an annual dividend of $0.16 per share and has a dividend yield of 0.5%. Swire Pacific pays out 9.2% of its earnings in the form of a dividend. Hikma Pharmaceuticals pays out 10.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Swire Pacific is clearly the better dividend stock, given its higher yield and lower payout ratio.

Analyst Ratings

This is a summary of current recommendations and price targets for Swire Pacific and Hikma Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Swire Pacific0000N/A
Hikma Pharmaceuticals01502.83

Profitability

This table compares Swire Pacific and Hikma Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Swire PacificN/AN/AN/A
Hikma PharmaceuticalsN/AN/AN/A

Summary

Swire Pacific beats Hikma Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

Fujitsu (OTCMKTS:FJTSY) and Hikma Pharmaceuticals (OTCMKTS:HKMPF) are both computer and technology companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, profitability, risk and dividends.

Insider and Institutional Ownership

0.1% of Fujitsu shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Fujitsu has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, Hikma Pharmaceuticals has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500.

Valuation & Earnings

This table compares Fujitsu and Hikma Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fujitsu$35.49 billion0.86$1.47 billion$1.4520.83
Hikma Pharmaceuticals$2.21 billion3.62$486 million$1.5022.00

Fujitsu has higher revenue and earnings than Hikma Pharmaceuticals. Fujitsu is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Dividends

Fujitsu pays an annual dividend of $0.28 per share and has a dividend yield of 0.9%. Hikma Pharmaceuticals pays an annual dividend of $0.16 per share and has a dividend yield of 0.5%. Fujitsu pays out 19.3% of its earnings in the form of a dividend. Hikma Pharmaceuticals pays out 10.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Analyst Recommendations

This is a breakdown of current ratings for Fujitsu and Hikma Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fujitsu00014.00
Hikma Pharmaceuticals01502.83

Profitability

This table compares Fujitsu and Hikma Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fujitsu3.95%10.86%4.69%
Hikma PharmaceuticalsN/AN/AN/A

Summary

Fujitsu beats Hikma Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Hikma Pharmaceuticals (OTCMKTS:HKMPF) and Ashtead Group (OTCMKTS:ASHTY) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability and earnings.

Volatility & Risk

Hikma Pharmaceuticals has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, Ashtead Group has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500.

Profitability

This table compares Hikma Pharmaceuticals and Ashtead Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hikma PharmaceuticalsN/AN/AN/A
Ashtead Group13.37%24.20%7.02%

Analyst Recommendations

This is a summary of recent recommendations for Hikma Pharmaceuticals and Ashtead Group, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hikma Pharmaceuticals01502.83
Ashtead Group07602.46

Dividends

Hikma Pharmaceuticals pays an annual dividend of $0.16 per share and has a dividend yield of 0.5%. Ashtead Group pays an annual dividend of $0.69 per share and has a dividend yield of 0.3%. Hikma Pharmaceuticals pays out 10.7% of its earnings in the form of a dividend. Ashtead Group pays out 7.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Valuation & Earnings

This table compares Hikma Pharmaceuticals and Ashtead Group's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hikma Pharmaceuticals$2.21 billion3.62$486 million$1.5022.00
Ashtead Group$5.84 billion4.85$936.90 million$8.8328.55

Ashtead Group has higher revenue and earnings than Hikma Pharmaceuticals. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than Ashtead Group, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

0.8% of Ashtead Group shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Ashtead Group beats Hikma Pharmaceuticals on 12 of the 14 factors compared between the two stocks.


Hikma Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ASSA ABLOY AB (publ) logo
ASAZY
ASSA ABLOY AB (publ)
1.2$15.01flat$31.67 billion$9.95 billion36.61Decrease in Short Interest
Amadeus IT Group logo
AMADY
Amadeus IT Group
0.5$69.43flat$31.28 billion$6.25 billion-239.41
CK Hutchison logo
CKHUY
CK Hutchison
0.7$8.03flat$30.95 billion$38.34 billion0.00Decrease in Short Interest
Swire Pacific logo
SWRAY
Swire Pacific
1.6$7.91flat$30.75 billion$10.93 billion3.15Decrease in Short Interest
News Coverage
Fujitsu logo
FJTSY
Fujitsu
0.9$30.20flat$30.60 billion$35.49 billion22.88Decrease in Short Interest
News Coverage
Gap Up
Ashtead Group logo
ASHTY
Ashtead Group
1.2$252.06flat$28.31 billion$5.84 billion34.81Decrease in Short Interest
Sampo Oyj logo
SAXPY
Sampo Oyj
0.8$24.07flat$26.95 billion$12.62 billion18.80
Compagnie Générale des Établissements Michelin Société en commandite par actions logo
MGDDY
Compagnie Générale des Établissements Michelin Société en commandite par actions
1.5$29.95flat$26.70 billion$27.03 billion13.80Analyst Report
Increase in Short Interest
Zalando logo
ZLNDY
Zalando
0.4$52.17flat$26.63 billion$7.26 billion237.15Analyst Downgrade
Gap Down
Associated British Foods logo
ASBFY
Associated British Foods
0.9$33.62flat$26.62 billion$18.00 billion32.02Analyst Upgrade
Decrease in Short Interest
Wilmar International logo
WLMIY
Wilmar International
0.7$40.59flat$25.64 billion$42.64 billion19.90Increase in Short Interest
Gap Up
Sunny Optical Technology (Group) logo
SNPTF
Sunny Optical Technology (Group)
0.5$22.39flat$24.56 billion$5.48 billion0.00Gap Up
Unicharm logo
UNICY
Unicharm
0.9$8.25flat$24.50 billion$6.55 billion63.47Gap Down
Kerry Group logo
KRYAY
Kerry Group
1.2$132.27flat$23.37 billion$8.11 billion29.99Analyst Upgrade
UniCredit logo
UNCFF
UniCredit
1.2$10.33flat$23.14 billion$25.52 billion10.76News Coverage
China CITIC Bank logo
CHCJY
China CITIC Bank
0.9$9.38flat$22.95 billion$47.62 billion0.00
China Mengniu Dairy logo
CIADY
China Mengniu Dairy
0.9$57.53flat$22.71 billion$11.44 billion37.85Analyst Upgrade
Shimano logo
SMNNY
Shimano
0.5$24.47flat$22.68 billion$3.33 billion41.84Decrease in Short Interest
Gap Up
Ocado Group logo
OCDDY
Ocado Group
0.4$59.90flat$22.43 billion$2.26 billion-78.82Analyst Upgrade
Decrease in Short Interest
SGS logo
SGSOY
SGS
1.3$29.53flat$22.34 billion$6.64 billion33.18Decrease in Short Interest
BAE Systems logo
BAESY
BAE Systems
1.4$27.69flat$22.29 billion$22.52 billion13.57Dividend Increase
Sysmex logo
SSMXY
Sysmex
0.6$51.87flat$21.73 billion$2.78 billion78.59
Suzuki Motor logo
SZKMY
Suzuki Motor
1.5$172.50flat$21.18 billion$32.03 billion20.46Decrease in Short Interest
Gap Down
Secom logo
SOMLY
Secom
1.3$21.29flat$19.87 billion$9.75 billion25.96Decrease in Short Interest
News Coverage
Nomura Research Institute logo
NRILY
Nomura Research Institute
1.1$30.81flat$19.74 billion$4.87 billion36.25Decrease in Short Interest
Eisai logo
ESALY
Eisai
1.3$66.46flat$19.71 billion$6.40 billion17.17Decrease in Short Interest
Ferrovial logo
FRRVY
Ferrovial
0.5$26.33flat$19.29 billion$6.78 billion0.00Increase in Short Interest
Rakuten logo
RKUNY
Rakuten
0.6$12.09flat$19.04 billion$11.60 billion-19.82Increase in Short Interest
Gap Up
Sino Biopharmaceutical logo
SBMFF
Sino Biopharmaceutical
0.8$1.00flat$18.88 billion$3.51 billion0.00Decrease in Short Interest
News Coverage
Eurofins Scientific logo
ERFSF
Eurofins Scientific
0.9$104.80flat$18.65 billion$5.19 billion46.37Gap Up
Deutsche Wohnen logo
DWHHF
Deutsche Wohnen
0.9N/AN/A$17.37 billion$937.88 million14.12
OMRON logo
OMRNY
OMRON
1.0$82.25flat$16.96 billion$6.24 billion0.00Increase in Short Interest
OMV Aktiengesellschaft logo
OMVJF
OMV Aktiengesellschaft
1.0$51.22flat$16.72 billion$26.28 billion-51.74Analyst Revision
News Coverage
Chow Tai Fook Jewellery Group logo
CJEWY
Chow Tai Fook Jewellery Group
1.2$16.65flat$16.65 billion$7.26 billion45.00
NN Group logo
NNGRY
NN Group
1.1$25.18flat$16.63 billion$22.92 billion7.82
bioMérieux logo
BMXMF
bioMérieux
0.5$137.28flat$16.25 billion$3.00 billion53.21News Coverage
Atlantia logo
ATASY
Atlantia
0.6$9.78flat$16.15 billion$14.13 billion108.67Decrease in Short Interest
Surgutneftegas Public Joint Stock logo
SGTZY
Surgutneftegas Public Joint Stock
0.1$4.52flat$15.86 billion$28.13 billion0.00
COSCO SHIPPING logo
CICOY
COSCO SHIPPING
0.8$7.25flat$14.81 billion$21.78 billion90.63News Coverage
Carrefour logo
CRRFY
Carrefour
1.1$3.59flat$14.68 billion$81.09 billion13.81Increase in Short Interest
Terna - Rete Elettrica Nazionale Società per Azioni logo
TEZNY
Terna - Rete Elettrica Nazionale Società per Azioni
0.6$21.86flat$14.64 billionN/A0.00Decrease in Short Interest
Schroders logo
SHNWF
Schroders
0.9$50.86flat$14.37 billion$3.24 billion20.10
Persimmon logo
PSMMY
Persimmon
1.3$88.53flat$14.12 billion$4.66 billion12.89
Sompo logo
SMPNY
Sompo
1.7$18.84flat$14.07 billion$34.60 billion10.70
Covestro logo
COVTY
Covestro
1.1$35.98flat$13.90 billion$13.90 billion60.98Analyst Report
Increase in Short Interest
News Coverage
Randstad logo
RANJY
Randstad
1.3$37.59flat$13.83 billion$26.52 billion48.19Analyst Downgrade
News Coverage
Kumba Iron Ore logo
KIROY
Kumba Iron Ore
0.8$14.17flat$13.69 billion$4.45 billion0.00Decrease in Short Interest
Brenntag logo
BNTGY
Brenntag
1.2$17.58flat$13.58 billion$14.36 billion25.85Increase in Short Interest
News Coverage
Yara International ASA logo
YARIY
Yara International ASA
1.5$25.30flat$13.57 billion$12.94 billion20.91Analyst Downgrade
Decrease in Short Interest
News Coverage
Edenred logo
EDNMY
Edenred
0.4$27.48flat$13.55 billion$1.82 billion0.00Increase in Short Interest
News Coverage
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.